(Reuters) – At an ill-fated press conference in 1984, U.S. Health and Human Services Secretary Margaret Heckler boldly predicted an effective AIDS vaccine would be available within just two years.But a string of failed attempts – punctuated by a 2007 trial in which a Merck vaccine appeared to make p

Siriporn Pooripussarakul1, Arthorn Riewpaiboon1* , David Bishai2, Charung Muangchana3 and Sripen Tantivess4 Abstract Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed vaccines are being considering for introduction into the Ex

Summary The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 20

The debate over the price of the vaccine against HPV has become intense http://www.bangkokpost.com/lifestyle/family/295534/stepping-up-the-campaign-against-cervical-cancerWhen it comes to making the shot against cervical cancer the national vaccine programme, which means girls be

This article is part 1 of the blog series: “Knowledge Translation: The Key to Turning Mathematical Models from a Black Box into a Powerful Tool for Policy Decision-Making” As health systems become more complex, decision-makers need tools that can help them evaluate long-term outcomes and choose

Introduction The world has been in the grip of the COVID-19 pandemic for over a year, costing many lives and bringing the ways of the world to a grinding halt. Among the strategies to respond to the pandemic, governments and the global community invested in developing vaccines. Those investments be

Siriporn Pooripussarakul Arthorn Riewpaiboon David Bishai Sripen Tantivess Charung Muangchana บทคัดย่อ การนำวัคซีนใหม่เข้ามาใช้ขึ้นอยู่กับหลายปัจจัย ได้แก่ นโยบาย แนวทางปฏิบัติ และการประเมินทางเศรษฐศาสตร์ ผู้ที่เกี่ยวข้องต่างๆ จึงพิจารณาปัจจัยสำคัญที่แตกต่างกันไปในการนำวัคซีนใหม่เข้าสู่โครงก

This project is part of the international Decision Support Initiative (iDSI), an innovative global partnership between leading government institutions, universities, and think tanks in the field of healthcare priority-setting. iDSI uniquely provides intellectual insight with hands-on field expertise, and delivers peer-to-peer support to policymaker

This article is part 2 of the blog series: “Knowledge Translation: The Key to Turning Mathematical Models from a Black Box into a Powerful Tool for Policy Decision-Making” In part 1 of this blog series, we discussed the role of mathematical models in supporting evidence-based public health decis

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,